Business Context and Reporting Period
This Form 8-K is filed by OncoGenex Pharmaceuticals, Inc. (noted in metadata as Achieve Life Sciences, Inc.) on November 10, 2008. The report discloses the Company's financial results for the quarter ended September 30, 2008, referencing a press release attached as Exhibit 99.1.
Key Financial Metrics
The filing text provided does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These figures are contained within the referenced press release (Exhibit 99.1), which is incorporated by reference but not included in the text of this 8-K summary.
Material Changes
The filing text does not provide specific data regarding material changes versus the prior comparable period. It serves solely as a notification that the quarterly results have been announced.
Guidance, Outlook, and Risks
The filing text does not include management commentary, forward-looking guidance, specific risk factors, or details on contingencies and unusual items. The document explicitly states that the attached press release shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934.
Investor Verification Checklist
- Verify the specific revenue and net loss figures in the attached Exhibit 99.1 (Press Release).
- Confirm the Company's cash position and runway as of September 30, 2008, from the press release.
- Review the press release for any updates on clinical trial progress or regulatory milestones.
- Note the discrepancy between the metadata company name ("ACHIEVE LIFE SCIENCES, INC.") and the filing issuer name ("ONCOGENEX PHARMACEUTICALS, INC.") to ensure correct entity tracking.